Abstract
The role of retroperitoneal lymph node dissection (RPLND) as first-line treatment for stage I or IIA/B testicular seminoma is not well defined. Using the National Cancer Data Base, we identified 365 men from 2004 to 2014 who received RPLND as primary treatment for testicular seminoma and found 5-year overall survival rates of 97.3% and 92.0% for those with stage I and IIA/B disease, respectively.
Author supplied keywords
Cite
CITATION STYLE
Tabakin, A. L., Shinder, B. M., Kim, S., Rivera-Nunez, Z., Polotti, C. F., Modi, P. K., … Jang, T. L. (2020). Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014. Clinical Genitourinary Cancer, 18(2), e194–e201. https://doi.org/10.1016/j.clgc.2019.10.018
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
